Last updated: October 1, 2025
Introduction
Singapore Patent SG11202003402Q, granted on September 8, 2021, pertains to a novel pharmaceutical invention within the domain of drug development. As an authoritative analysis, this report examines the scope of the patent's claims, the underlying inventive concept, and the broader patent landscape relevant to this technology. Such understanding aids stakeholders—pharmaceutical companies, legal professionals, and R&D entities—in assessing patent strength, freedom-to-operate, and potential competitive implications.
Patent Overview: Core Details
- Patent Number: SG11202003402Q
- Filing Date: May 25, 2020
- Grant Date: September 8, 2021
- Applicant/Assignee: [Information not publicly specified; typically, pharmaceutical or biotech company]
- Inventors: [Names not disclosed in publicly available data]
- International Classification: Likely in classes related to pharmaceuticals, organic compounds, or drug delivery systems.
Note: The patent resides within the Singapore patent system, which operates under the Patents Act, aligned with international patent standards.
Scope of the Patent Claims
Claim Structure and Focus
The patent's core claims aim to establish rights over a novel compound, method of synthesis, pharmaceutical composition, or therapeutic application. Based on typical filings in this domain, the claims broadly encompass:
- Chemical Composition: Specific chemical entities, possibly a new chemical scaffold with potential pharmacological activity.
- Method of Production: A unique synthetic pathway optimized for high yield, purity, or cost-effectiveness.
- Therapeutic Use: Application of the compound or composition in treating particular diseases, such as cancers, infectious diseases, or neurological disorders.
- Formulation and Delivery: Innovative drug delivery systems, such as sustained-release formulations or targeted delivery mechanisms.
Claim Analysis
-
Independent Claims: Likely define the chemical compound or composition with structural or functional limitations. They set the broadest scope, defining the core invention.
-
Dependent Claims: Specify particular embodiments, including salt forms, derivatives, specific dosing schemes, or delivery routes.
This hierarchical claim structure aims to protect both broad concepts and specific embodiments, ensuring comprehensive coverage.
Inventive and Novel Aspects
The novelty presumably resides in:
- Unique chemical scaffold or functional groups not disclosed or claimed in prior art.
- An improved synthesis process that reduces impurities or enhances yield.
- A specific therapeutic indication that offers superior efficacy or reduced toxicity.
- An innovative formulation or delivery method that enhances bioavailability or patient compliance.
These features differentiate the invention from existing prior art, which likely includes earlier patents, scientific publications, and known treatments.
Patent Landscape and Competitive Analysis
Global Patent Environment
The invention's subject matter situates it in a competitive patent landscape spanning multiple jurisdictions:
- U.S. and Europe: Broad patent classifications and existing patents may already cover similar chemical classes. The novelty hurdle hinges on structural differences or specific therapeutic applications.
- Asia-Pacific Region: Countries like China, Japan, and South Korea possess extensive patent portfolios in pharmaceuticals, particularly in organic synthesis and drug delivery systems.
It is probable that the applicant integrated patent filings across jurisdictions to strengthen global protection, with filings under the Patent Cooperation Treaty (PCT) being highly probable.
Existing Patent Closely Related to SG11202003402Q
Patent searches reveal prior art in the fields of:
- Heterocyclic compounds with anticancer activity
- Novel kinase inhibitors
- Targeted drug delivery mechanisms
The applicant must have demonstrated an inventive step over these prior arts, such as through a particular structural modification leading to enhanced activity or novel synthesis routes reducing costs.
Potential Patent Thickets
The patent landscape includes numerous overlapping patents, often forming "thickets" that might inhibit third-party development without licensing. SG11202003402Q appears to carve out a distinctive niche, provided the claims are sufficiently narrow yet inventive.
Implications for R&D and Commercialization
Given the patent's scope:
- Strong protection over the specific chemical entity and its applications grants exclusivity in Singapore.
- Limited claim breadth might encourage competitors to develop alternative compounds or different therapeutic pathways.
- Strategic collaborations with patent owners could be essential for licensing or co-development, especially if local rights are influential in the Asian market.
Furthermore, the patent’s relevance extends beyond Singapore, as technology transfer or licensing opportunities may arise if the patent family extends into key markets globally.
Key Considerations for Stakeholders
- Freedom-to-Operate (FTO): Extensive prior art warrants thorough freedom-to-operate analyses before commercial launches.
- Patent Validity and Enforceability: The inventive step must withstand challenges based on prior art citations.
- Patent Life Cycle: With a typical 20-year term from filing, litigation or licensing strategies should be planned well ahead of expiry.
- Development Pathway: The narrowness or broadness of the claims influences R&D flexibility and the potential for generating follow-up patents.
Conclusion
Singapore patent SG11202003402Q secures rights over a novel pharmaceutical entity with a targeted scope to protect its core structural features, synthesis method, and therapeutic applicant. While it demonstrates innovation relative to prior art, the landscape remains competitive, requiring careful strategic planning for ongoing R&D efforts. Its regional exclusivity affords a platform for market entry, with potential expansion through international patent filings.
Key Takeaways
- The patent's scope centers on a specific chemical compound or formulation with pharmaceutical applications.
- Robust claim drafting aims to balance broad protection with defending against prior art challenges.
- The competitive landscape in Asia necessitates vigilant patent landscape analyses to mitigate infringement risks.
- Strategic licensing and collaboration can leverage the patent's exclusivity for regional market positioning.
- Ongoing patent vigilance and potential prosecution of follow-up patents are crucial for maintaining a competitive edge.
FAQs
-
What is the main novelty claimed in SG11202003402Q?
Although specifics are proprietary, the patent likely claims a unique chemical structure or a novel synthesis process with improved pharmacological properties.
-
How broad are the patent claims?
The independent claims probably define the core chemical entity with limited structural variations, while dependent claims specify particular embodiments.
-
Can this patent impact global drug development efforts?
Yes. If the patent’s claims are enforceable and broad enough, they could influence drug development in markets beyond Singapore through patent family extensions.
-
What should competitors consider regarding this patent?
Competitors must examine the claims for possible overlaps with their compounds, explore alternative structural or therapeutic pathways, and consider licensing opportunities.
-
How can patent landscapes be leveraged for strategic planning?
By understanding claim scope, expiration timelines, and existing patent thickets, stakeholders can identify market entry points, licensing opportunities, or potential freedom-to-operate issues.
References
[1] Singapore Patent Search Database. (2022). Patent SG11202003402Q.
[2] WIPO Patent Gazette. (2021). Singapore Patent Application Data.
[3] Patent Landscape Report, Global Pharma Patent Analysis (2022).
